Kyle graduated from Villanova University in May 2021 with a B.S. in Chemistry and Biochemistry. As an undergraduate, he conducted research under the supervision of Dr. Konstantinos Agrios, synthesizing novel small molecule inhibitors of Factor D. In the fall of 2021, Kyle joined the Hergenrother lab and is now working on the synthesis of anticancer compounds derived from the Complexity-to-Diversity strategy.